MARKET

CINGW

CINGW

Cingulate
NASDAQ
0.0385
-0.0004
-1.03%
Closed 09:52 12/04 EST
OPEN
0.0385
PREV CLOSE
0.0389
HIGH
0.0385
LOW
0.0385
VOLUME
2.00K
TURNOVER
--
52 WEEK HIGH
0.1750
52 WEEK LOW
0.0200
MARKET CAP
--
P/E (TTM)
-0.0072
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CINGW last week (1124-1128)?
Weekly Report · 3d ago
Weekly Report: what happened at CINGW last week (1117-1121)?
Weekly Report · 11/24 09:19
Cingulate Inc. Signs Exclusive Commercial Supply Agreement with Bend Bio Sciences
Reuters · 11/18 21:28
Weekly Report: what happened at CINGW last week (1110-1114)?
Weekly Report · 11/17 09:19
Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectations
Reuters · 11/13 13:09
Cingulate Inc. posts third quarter loss of $6.0 million
Reuters · 11/13 13:00
CINGULATE Q3 NET INCOME USD -7.3 MILLION VS. IBES ESTIMATE USD -3.82 MILLION
Reuters · 11/13 13:00
Cingulate Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Bryan Wade Downey
Reuters · 11/10 23:00
More
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Webull offers Cingulate Inc stock information, including NASDAQ: CINGW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CINGW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CINGW stock methods without spending real money on the virtual paper trading platform.